## Jeffrey D Zajac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9064255/publications.pdf

Version: 2024-02-01

38660 45213 10,262 233 50 90 citations h-index g-index papers 243 243 243 9917 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The impact of the first three months of the COVID-19 pandemic on the Australian trans community. International Journal of Transgender Health, 2023, 24, 281-291.	1.1	18
2	The Effect of Gender-Affirming Hormones on Gender Dysphoria, Quality of Life, and Psychological Functioning in Transgender Individuals: A Systematic Review. Transgender Health, 2023, 8, 6-21.	1.2	21
3	Effects of estradiol on fat in men undergoing androgen deprivation therapy: a randomized trial. European Journal of Endocrinology, 2022, 186, 9-23.	1.9	4
4	The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments. Obesity Reviews, 2022, 23, e13429.	3.1	9
5	Effect of estradiol on cognition in men undergoing androgen deprivation therapy: A randomized placeboâ€controlled trial. Clinical Endocrinology, 2022, 97, 622-633.	1.2	3
6	Testosterone concentrations and prescription patterns of $1\%$ testosterone gel in transgender and gender diverse individuals. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882210835.	1.4	3
7	Gender-affirming hormone therapy induces specific DNA methylation changes in blood. Clinical Epigenetics, 2022, 14, 24.	1.8	17
8	Prescription Patterns and Testosterone Concentrations Achieved with AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals. Journal of Sexual Medicine, 2022, 19, 1049-1054.	0.3	0
9	The AR in bone marrow progenitor cells protects against short-term high caloric diet induced weight gain in male mice Journal of Molecular Endocrinology, 2022, , .	1.1	O
10	Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial. Trials, 2022, 23, 335.	0.7	2
11	Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial. European Journal of Endocrinology, 2022, 187, 241-256.	1.9	2
12	Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. Internal Medicine Journal, 2021, 51, 873-878.	0.5	16
13	The Informed Consent Model of Care for Accessing Gender-Affirming Hormone Therapy Is Associated With High Patient Satisfaction. Journal of Sexual Medicine, 2021, 18, 201-208.	0.3	31
14	The Health and Well-Being of Transgender Australians: A National Community Survey. LGBT Health, 2021, 8, 42-49.	1.8	57
15	Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 893-901.	1.8	28
16	A systematic review of antiandrogens and feminization in transgender women. Clinical Endocrinology, 2021, 94, 743-752.	1,2	32
17	Insulin resistance in transgender individuals correlates with android fat mass. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098568.	1.4	19
18	Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110121.	1.4	0

#	Article	IF	CITATIONS
19	Factors associated with suicide attempts among Australian transgender adults. BMC Psychiatry, 2021, 21, 81.	1.1	25
20	Effect of Testosterone Treatment on Bone Microarchitecture and Bone Mineral Density in Men: A 2-Year RCT. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3143-e3158.	1.8	27
21	Changes in white adipose tissue gene expression in a randomized control trial of dieting obese men with lowered serum testosterone alone or in combination with testosterone treatment. Endocrine, 2021, 73, 463-471.	1.1	0
22	The calcitonin receptor regulates osteocyte lacunae acidity during lactation in mice. Journal of Endocrinology, 2021, 249, 31-41.	1.2	2
23	Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial. Journal of Clinical Neuroscience, 2021, 86, 103-109.	0.8	0
24	Predicting allâ€cause unplanned readmission within 30 days of discharge using electronic medical record data: A multiâ€centre study. International Journal of Clinical Practice, 2021, 75, e14306.	0.8	3
25	Neuronal androgen receptor is required for activity dependent enhancement of peripheral nerve regeneration. Developmental Neurobiology, 2021, 81, 411-423.	1.5	7
26	Diabetes care for hospital patients in Australia needs repair. Medical Journal of Australia, 2021, 215, 114-115.	0.8	0
27	Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study. Frontiers in Endocrinology, 2021, 12, 717766.	1.5	31
28	Distinct roles of androgen receptor, estrogen receptor alpha, and BCL6 in the establishment of sex-biased DNA methylation in mouse liver. Scientific Reports, 2021, 11, 13766.	1.6	7
29	Genetic Depletion of Amylin/Calcitonin Receptors Improves Memory and Learning in Transgenic Alzheimer's Disease Mouse Models. Molecular Neurobiology, 2021, 58, 5369-5382.	1.9	7
30	Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia. Frontiers in Endocrinology, 2021, 12, 667403.	1.5	2
31	Older People With Type 2 Diabetes–Individualising Management With a Specialised Community Team (OPTIMISE): Perspectives of Participants on Care. Clinical Diabetes, 2021, 39, 397-410.	1.2	0
32	Multicentric EBV-associated smooth muscle tumour with involvement of the pituitary gland. Pathology, 2021, , .	0.3	1
33	Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions. Journal of Diabetes and Its Complications, 2020, 34, 107465.	1.2	4
34	Biomechanical Leg Muscle Function During Stair Ambulation in Men Receiving Androgen Deprivation Therapy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1715-1722.	1.7	2
35	Australian endocrinologists need more training in transgender health: A national survey. Clinical Endocrinology, 2020, 92, 247-257.	1.2	5
36	Prevalence of Autism Spectrum Disorder and Attention-Deficit Hyperactivity Disorder Amongst Individuals with Gender Dysphoria: A Systematic Review. Journal of Autism and Developmental Disorders, 2020, 50, 695-706.	1.7	49

#	Article	lF	CITATIONS
37	Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. Nature, 2020, 587, 460-465.	13.7	55
38	Relationships between body mass index with oral estradiol dose and serum estradiol concentration in transgender adults undergoing feminising hormone therapy. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882092454.	1.4	4
39	Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man. Clinical Endocrinology, 2020, 93, 355-357.	1.2	10
40	Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial. Journal of Bone and Mineral Research, 2020, 35, 1871-1880.	3.1	10
41	Global Coagulation Assays in Transgender Women on Oral and Transdermal Estradiol Therapy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2369-e2377.	1.8	12
42	Sex-specific adipose tissue imprinting of regulatory T cells. Nature, 2020, 579, 581-585.	13.7	141
43	Intestinal Pseudo-Obstruction and Livedo Reticularis: Rare Manifestations of Catecholamine Excess. American Journal of Medicine, 2020, 133, e526-e527.	0.6	2
44	Androgens stimulate erythropoiesis through the DNAâ€binding activity of the androgen receptor in nonâ€hematopoietic cells. European Journal of Haematology, 2020, 105, 247-254.	1.1	8
45	Non-Binary and Binary Gender Identity in Australian Trans and Gender Diverse Individuals. Archives of Sexual Behavior, 2020, 49, 2673-2681.	1.2	39
46	Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man. , 2020, 93, 355.		1
47	Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. World Journal of Diabetes, 2020, $11$ , 66-77.	1.3	54
48	Bone Microarchitecture in Transgender Adults: A Cross-Sectional Study. Journal of Bone and Mineral Research, 2020, 37, 643-648.	3.1	13
49	Crossâ€sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare. Internal Medicine Journal, 2019, 49, 182-188.	0.5	20
50	Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocrine Connections, 2019, 8, 935-940.	0.8	33
51	Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes. Diabetes Research and Clinical Practice, 2019, 154, 130-137.	1.1	7
52	Position statement on the hormonal management of adult transgender and gender diverse individuals. Medical Journal of Australia, 2019, 211, 127-133.	0.8	45
53	Metformin: time to review its role and safety in chronic kidney disease. Medical Journal of Australia, 2019, 211, 37-42.	0.8	25
54	Routine HbA1c among hematology and oncology inpatients: Diabetes-status and hospital-outcomes. Diabetes Research and Clinical Practice, 2019, 152, 71-78.	1.1	0

#	Article	IF	CITATIONS
55	Selective Loss of Levator Ani and Leg Muscle Volumes in Men Undergoing Androgen Deprivation Therapy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2229-2238.	1.8	6
56	The androgen receptor in the hypothalamus positively regulates hind-limb muscle mass and voluntary physical activity in adult male mice. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 187-194.	1,2	10
57	Feasibility of using a transition diabetes team to commence injectable therapies postdischarge from a tertiary hospital: a pilot, randomised controlled trial. BMJ Open, 2019, 9, e023583.	0.8	2
58	Health Needs of Trans and Gender Diverse Adults in Australia: A Qualitative Analysis of a National Community Survey. International Journal of Environmental Research and Public Health, 2019, 16, 5088.	1.2	44
59	Is Thermal Imaging a Useful Predictor of the Healing Status of Diabetes-Related Foot Ulcers? A Pilot Study. Journal of Diabetes Science and Technology, 2019, 13, 561-567.	1.3	17
60	Older People With Type 2 Diabetesâ€"Individualizing Management With a Specialized (OPTIMISE) Community Team: Protocol for a Safety and Feasibility Mixed Methods Study. JMIR Research Protocols, 2019, 8, e13986.	0.5	2
61	Cortical Matrix Mineral Density Measured Noninvasively in Pre- and Postmenopausal Women and a Woman With Vitamin D–Dependent Rickets. Journal of Bone and Mineral Research, 2018, 33, 1312-1317.	3.1	9
62	The androgen receptor in bone marrow progenitor cells negatively regulates fat mass. Journal of Endocrinology, 2018, 237, 15-27.	1.2	5
63	Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer. European Journal of Endocrinology, 2018, 179, 21-29.	1.9	13
64	The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. Diabetes Care, 2018, 41, 1172-1179.	4.3	57
65	Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology, 2018, 178, 565-576.	1.9	13
66	Flash glucose monitoringâ€"using technology to improve outcomes for patients with diabetes. Australian Journal of Rural Health, 2018, 26, 453-454.	0.7	7
67	Sociodemographic and Clinical Characteristics of Transgender Adults in Australia. Transgender Health, 2018, 3, 229-238.	1.2	71
68	Routine use of HbA1c amongst inpatients hospitalised with decompensated heart failure and the association of dysglycaemia with outcomes. Scientific Reports, 2018, 8, 13564.	1.6	5
69	Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial. Scientific Reports, 2018, 8, 9099.	1.6	20
70	High-Resolution Spectral Analysis Accurately Identifies the Bacterial Signature in Infected Chronic Foot Ulcers in People With Diabetes. International Journal of Lower Extremity Wounds, 2018, 17, 78-86.	0.6	5
71	Genderâ€affirming hormone therapy and the risk of sex hormoneâ€dependent tumours in transgender individuals—A systematic review. Clinical Endocrinology, 2018, 89, 700-711.	1.2	35
72	Using routine HbA1c measurements in stroke and the associations of dysglycaemia with stroke outcomes. Journal of Diabetes and Its Complications, 2018, 32, 1056-1061.	1.2	4

#	Article	IF	Citations
73	Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 44-56.	1.8	24
74	Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case–control study. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 102-112.	2.9	34
75	The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment. Clinical Endocrinology, 2017, 87, 336-343.	1.2	31
76	Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. International Journal of Obesity, 2017, 41, 420-426.	1.6	34
77	Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use. Diabetes Research and Clinical Practice, 2017, 134, 29-37.	1.1	6
78	Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 56-64.	1.2	22
79	Androgen Action via the Androgen Receptor in Neurons Within the Brain Positively Regulates Muscle Mass in Male Mice. Endocrinology, 2017, 158, 3684-3695.	1.4	26
80	Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure. Bone, 2017, 103, 131-135.	1.4	15
81	Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clinical Endocrinology, 2017, 86, 388-394.	1.2	40
82	Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients. Frontiers in Endocrinology, 2017, 8, 53.	1.5	3
83	Review of Evidence for Adult Diabetic Ketoacidosis Management Protocols. Frontiers in Endocrinology, 2017, 8, 106.	1.5	58
84	Using Automated HbA1c Testing to Detect Diabetes Mellitus in Orthopedic Inpatients and Its Effect on Outcomes. PLoS ONE, 2017, 12, e0168471.	1.1	12
85	The problem with modern endocrinology. Medical Journal of Australia, 2016, 205, 159-159.	0.8	0
86	Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Medical Journal of Australia, 2016, 205, 228-231.	0.8	45
87	Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Medical Journal of Australia, 2016, 205, 173-178.	0.8	88
88	Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes. Clinical Endocrinology, 2016, 84, 55-62.	1.2	13
89	Correlation of visceral adipose tissue measured by Lunar Prodigy dual X-ray absorptiometry with MRI and CT in older men. International Journal of Obesity, 2016, 40, 1325-1328.	1.6	52
90	Muscle-specific androgen receptor deletion shows limited actions in myoblasts but not in myofibers in different muscles in vivo. Journal of Molecular Endocrinology, 2016, 57, 125-138.	1.1	23

#	Article	IF	Citations
91	Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial. BMC Medicine, 2016, 14, 153.	2.3	88
92	Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation. Endocrine-Related Cancer, 2016, 23, R15-R26.	1.6	13
93	Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. European Journal of Endocrinology, 2016, 175, 229-237.	1.9	55
94	Osteoclast TGF- $\hat{l}^2$ Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. Journal of Bone and Mineral Research, 2016, 31, 76-85.	3.1	73
95	Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. Journal of Bone and Mineral Research, 2016, 31, 65-75.	3.1	119
96	Impaired glucose metabolism and exercise capacity with muscle-specific glycogen synthase 1 (gys1) deletion in adult mice. Molecular Metabolism, 2016, 5, 221-232.	3.0	45
97	Association of sex hormone-binding globulin and free testosterone with mortality in men with type 2 diabetes mellitus. European Journal of Endocrinology, 2016, 174, 59-68.	1.9	28
98	Bowel perforation complicating an ACTH-secreting phaeochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	12
99	Androgen Receptor Action in Osteoblasts in Male Mice Is Dependent on Their Stage of Maturation. Journal of Bone and Mineral Research, 2015, 30, 809-823.	3.1	17
100	Inpatient HbA1c testing: a prospective observational study. BMJ Open Diabetes Research and Care, 2015, 3, e000113.	1.2	30
101	Response to Wnt Signaling Pathways. Journal of Bone and Mineral Research, 2015, 30, 2135-2136.	3.1	1
102	The androgen receptor has no direct antiresorptive actions in mouse osteoclasts. Molecular and Cellular Endocrinology, 2015, 411, 198-206.	1.6	34
103	Sex steroids levels in chronic kidney disease and kidney transplant recipients: associations with disease severity and prediction of mortality. Clinical Endocrinology, 2015, 82, 767-775.	1.2	31
104	A Role for the Calcitonin Receptor to Limit Bone Loss During Lactation in Female Mice by Inhibiting Osteocytic Osteolysis. Endocrinology, 2015, 156, 3203-3214.	1.4	47
105	Effect of Testosterone Treatment on Constitutional and Sexual Symptoms in Men With Type 2 Diabetes in a Randomized, Placebo-Controlled Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3821-3828.	1.8	55
106	Human androgen deficiency: insights gained from androgen receptor knockout mouse models. Asian Journal of Andrology, 2014, 16, 169.	0.8	54
107	Normal phenotype in conditional androgen receptor (AR) exon 3-floxed <i>neomycin</i> -negative male mice. Endocrine Research, 2014, 39, 130-135.	0.6	7
108	Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. Endocrine-Related Cancer, 2014, 21, R371-R394.	1.6	50

#	Article	IF	Citations
109	Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2098-2107.	4.3	135
110	Testosterone levels increase in association with recovery from acute fracture in men. Osteoporosis International, 2014, 25, 2027-2033.	1.3	5
111	Expression of androgen receptor target genes in skeletal muscle. Asian Journal of Andrology, 2014, 16, 675.	0.8	42
112	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. Reproductive Biology and Endocrinology, 2013, 11, 40.	1.4	7
113	Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for nonâ€metastatic prostate cancer: implementation of standardized management guidelines. Andrology, 2013, 1, 583-589.	1.9	49
114	Expression of Wnt signaling skeletal development genes in the cartilaginous fish, elephant shark (Callorhinchus milii). General and Comparative Endocrinology, 2013, 193, 1-9.	0.8	4
115	Osteocalcin, Undercarboxylated Osteocalcin, and Glycemic Control in Human Subjects. , 2013, , 181-188.		1
116	Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 603-616.	2.2	71
117	Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status. Andrology, 2013, 1, 906-912.	1.9	26
118	A Comparison of Precipitants and Mortality When Acute Decompensated Heart Failure Occurs in the Community and Hospital Settings. Heart Lung and Circulation, 2012, 21, 439-443.	0.2	10
119	Identification of gene pathways altered by deletion of the androgen receptor specifically in mineralizing osteoblasts and osteocytes in mice. Journal of Molecular Endocrinology, 2012, 49, 1-10.	1.1	33
120	Hematological changes during androgen deprivation therapy. Asian Journal of Andrology, 2012, 14, 187-192.	0.8	52
121	Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual. Transgenic Research, 2012, 21, 885-893.	1.3	82
122	Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. Clinical Endocrinology, 2012, 77, 323-328.	1.2	69
123	Kennedy's Disease. Advances in Experimental Medicine and Biology, 2012, , 153-168.	0.8	5
124	Kennedy's disease: clinical significance of tandem repeats in the androgen receptor. Advances in Experimental Medicine and Biology, 2012, 769, 153-68.	0.8	4
125	Management of Side Effects of Androgen Deprivation Therapy. Endocrinology and Metabolism Clinics of North America, 2011, 40, 655-671.	1.2	65
126	The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone, 2011, 48, 354-361.	1.4	30

#	Article	IF	Citations
127	Bone and metabolic health in patients with nonâ€metastatic prostate cancer who are receiving androgen deprivation therapy. Medical Journal of Australia, 2011, 194, 301-306.	0.8	87
128	Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?. Clinical Endocrinology, 2011, 74, 289-293.	1.2	60
129	Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology, 2011, 74, 377-383.	1.2	169
130	Ornithine decarboxylase is upregulated by the androgen receptor in skeletal muscle and regulates myoblast proliferation. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E172-E179.	1.8	42
131	Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E767-E778.	1.8	63
132	Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 247-256.	1.2	94
133	Medical identity fraud in the United States: could it happen here?. Medical Journal of Australia, 2010, 192, 119-119.	0.8	3
134	DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. Journal of Endocrinology, 2010, 206, 93-103.	1.2	37
135	Structural Decay of Bone Microarchitecture in Men with Prostate Cancer Treated with Androgen Deprivation Therapy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E456-E463.	1.8	83
136	Women's health in the United States. Medical Journal of Australia, 2009, 190, 53-53.	0.8	0
137	The high cost of drugs in the United States. Medical Journal of Australia, 2009, 190, 352-352.	0.8	0
138	Why is health care so expensive in the United States?. Medical Journal of Australia, 2009, 190, 175-175.	0.8	0
139	President Obama's health care plan. Medical Journal of Australia, 2009, 191, 54-54.	0.8	2
140	Sertoli Cell Androgen Receptor DNA Binding Domain Is Essential for the Completion of Spermatogenesis. Endocrinology, 2009, 150, 4755-4765.	1.4	66
141	Low testosterone and anaemia in men with type 2 diabetes. Clinical Endocrinology, 2009, 70, 547-553.	1.2	53
142	Familial hyperaldosteronism type 1 in pregnancy. Internal Medicine Journal, 2009, 39, 135-136.	0.5	6
143	Mineralization and Bone Resorption Are Regulated by the Androgen Receptor in Male Mice. Journal of Bone and Mineral Research, 2009, 24, 621-631.	3.1	98
144	Calcitonin Receptor Plays a Physiological Role to Protect Against Hypercalcemia in Mice. Journal of Bone and Mineral Research, 2008, 23, 1182-1193.	3.1	76

#	Article	IF	CITATIONS
145	Intermittent Fugu parathyroid hormone 1 ( $1\hat{a}\in$ 34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone, 2008, 42, 1164-1174.	1.4	10
146	Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell, 2008, 135, 825-837.	13.5	751
147	Generation and analysis of an androgen-responsive myoblast cell line indicates that androgens regulate myotube protein accretion. Journal of Endocrinological Investigation, 2008, 31, 910-918.	1.8	18
148	A floxed allele of the <i>androgen receptor</i> gene causes hyperandrogenization in male mice. Physiological Genomics, 2008, 33, 133-137.	1.0	30
149	Impaired skeletal muscle development and function in male, but not female, genomic <i>androgen receptor</i> knockout mice. FASEB Journal, 2008, 22, 2676-2689.	0.2	179
150	Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1834-1840.	1.8	365
151	Severe Subfertility in Mice with Androgen Receptor Inactivation in Sex Accessory Organs But Not in Testis. Endocrinology, 2008, 149, 3330-3338.	1.4	39
152	The development of the parathyroid gland: from fish to human. Current Opinion in Nephrology and Hypertension, 2008, 17, 353-356.	1.0	36
153	Outcomes for general medical inpatients with diabetes mellitus and new hyperglycaemia. Medical Journal of Australia, 2008, 188, 340-343.	0.8	34
154	Oestradiol-induced spermatogenesis requires a functional androgen receptor. Reproduction, Fertility and Development, 2008, 20, 861.	0.1	24
155	What Australia can learn from the US health care system. Medical Journal of Australia, 2008, 189, 644-644.	0.8	0
156	Female Mice Haploinsufficient for an Inactivated Androgen Receptor (AR) Exhibit Age-Dependent Defects That Resemble the AR Null Phenotype of Dysfunctional Late Follicle Development, Ovulation, and Fertility. Endocrinology, 2007, 148, 3674-3684.	1.4	127
157	Disruption of Prostate Epithelial Androgen Receptor Impedes Prostate Lobe-Specific Growth and Function. Endocrinology, 2007, 148, 2264-2272.	1.4	75
158	Men with Kennedy disease have a reduced risk of androgenetic alopecia. British Journal of Dermatology, 2007, 157, 290-294.	1.4	44
159	Osteoblast Deletion of Exon 3 of the Androgen Receptor Gene Results in Trabecular Bone Loss in Adult Male Mice. Journal of Bone and Mineral Research, 2007, 22, 347-356.	3.1	117
160	Spinobulbar Muscular Atrophy (Kennedy's Disease). , 2007, , 553-561.		0
161	Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus. Lipids in Health and Disease, 2006, 5, 29.	1.2	5
162	Effects of Amylin Deficiency on Trabecular Bone in Young Mice Are Sex-Dependent. Calcified Tissue International, 2006, 78, 398-403.	1.5	26

#	Article	IF	Citations
163	Double-strand DNA break repair with replication slippage on two strands: a novel mechanism of deletion formation. Human Mutation, 2006, 27, 483-489.	1.1	9
164	Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E506-E516.	1.8	108
165	A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clinical Endocrinology, 2005, 62, 99-104.	1.2	53
166	Androgen regulation of satellite cell function. Journal of Endocrinology, 2005, 186, 21-31.	1.2	113
167	Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. Journal of Molecular Endocrinology, 2005, 35, 547-555.	1.1	133
168	Age-dependent differences in androgen binding affinity in a family with spinal and bulbar muscular atrophy. Neurological Research, 2005, 27, 548-551.	0.6	5
169	Hormonal Therapies for Individuals with Intersex Conditions. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 19-29.	1.8	41
170	11: Androgen deficiency and replacement therapy in men. Medical Journal of Australia, 2004, 180, 529-535.	0.8	44
171	The public hospital of the future. Medical Journal of Australia, 2004, 180, 47-47.	0.8	0
172	Androgen deficiency and replacement therapy in men. Medical Journal of Australia, 2004, 181, 286-287.	0.8	1
173	Kennedy's disease: pathogenesis and clinical approaches. Internal Medicine Journal, 2004, 34, 279-286.	0.5	40
174	Genetically Modified Animal Models as Tools for Studying Bone and Mineral Metabolism. Journal of Bone and Mineral Research, 2004, 19, 882-892.	3.1	35
175	Polymorphic CAG repeat length in the androgen receptor gene and association with neurodegeneration in a heterozygous female carrier of Kennedy?s disease. Journal of Neurology, 2004, 251, 35-41.	1.8	32
176	Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Research and Treatment, 2004, 88, 239-246.	1.1	32
177	Transgenic mice that express Cre recombinase in osteoclasts. Genesis, 2004, 39, 178-185.	0.8	91
178	Novel androgen receptor gene mutations in Australian patients with complete androgen insensitivity syndrome. Human Mutation, 2004, 23, 287-287.	1.1	18
179	Application of Differential Display in the Identification of Androgenâ€Regulated Genes. Endocrine Research, 2004, 30, 69-82.	0.6	2
180	Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. Journal of Cell Biology, 2004, 164, 509-514.	2.3	183

#	Article	IF	Citations
181	Identification of a Parathyroid Hormone in the Fish Fugu rubripes. Journal of Bone and Mineral Research, 2003, 18, 1326-1331.	3.1	62
182	Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney. Diabetologia, 2003, 46, 1338-1347.	2.9	21
183	Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. Journal of Molecular Endocrinology, 2003, 31, 449-459.	1.1	48
184	The public hospital of the future. Medical Journal of Australia, 2003, 179, 250-252.	0.8	45
185	Endocrinology in the 21st century. Medical Journal of Australia, 2003, 179, 378-378.	0.8	0
186	Aberrant cryptic responsiveness of the pCAT $<$ sup $>$ Â $^{\odot}<$ sup $>$ 3- and pGL3-promoter reporter vectors. BioTechniques, 2003, 35, 332-339.	0.8	4
187	Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106-01) cell line results in growth inhibition. Bone, 2002, 31, 598-605.	1.4	21
188	Prevention of Diabetes-Induced Albuminuria in Transgenic Rats Overexpressing Human Aldose Reductase. Endocrine, 2002, 18, 47-56.	2.2	4
189	Low-Intensity Pulsed Ultrasound Stimulates a Bone-Forming Response in UMR-106 Cells. Biochemical and Biophysical Research Communications, 2001, 286, 443-450.	1.0	105
190	Relationships with serum parathyroid hormone in old institutionalized subjects. Clinical Endocrinology, 2001, 54, 583-592.	1.2	35
191	A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer, 2001, 92, 941-949.	2.0	60
192	Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplantation, 2000, 26, 1089-1095.	1.3	117
193	Use, misuse and abuse of androgens. Medical Journal of Australia, 2000, 172, 220-224.	0.8	99
194	Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. Journal of Molecular Endocrinology, 2000, 25, 85-96.	1.1	238
195	Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene. Diabetologia, 1999, 42, 419-426.	2.9	21
196	Falls Relate to Vitamin D and Parathyroid Hormone in an Australian Nursing Home and Hostel. Journal of the American Geriatrics Society, 1999, 47, 1195-1201.	1.3	186
197	Differential regulation of the parathyroid hormone-related protein gene P1 and P3 promoters by cAMP. Molecular and Cellular Endocrinology, 1998, 138, 173-184.	1.6	25
198	DISORDERS OF SEXUAL DIFFERENTIATION. Endocrinology and Metabolism Clinics of North America, 1998, 27, 945-967.	1.2	27

#	Article	IF	Citations
199	Androgen Insensitivity Syndrome in the Era of Molecular Genetics and the Internet: A Point of View. Journal of Pediatric Endocrinology and Metabolism, 1998, 11, 3-9.	0.4	57
200	Germline Dinucleotide Mutation in Codon 883 of theRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 Mutation. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3902-3904.	1.8	216
201	Localization of functional domains in the androgen receptor. Journal of Steroid Biochemistry and Molecular Biology, 1997, 62, 233-242.	1.2	139
202	Intersex disorders: shedding light on male sexual differentiation beyond SRY. Clinical Endocrinology, 1997, 46, 101-108.	1.2	26
203	Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. Journal of the Neurological Sciences, 1996, 135, 149-157.	0.3	42
204	Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse: An acquired defect. Metabolism: Clinical and Experimental, 1996, 45, 622-626.	1.5	19
205	A type I collagen substrate increases PTH/PTHrP receptor mRNA expression and suppresses PTHrP mRNA expression in UMR106–06 osteoblast-like cells. Journal of Endocrinology, 1996, 150, 299-308.	1.2	16
206	TRANSCRIPTIONAL CONTROL AND THE REGULATION OF ENDOCRINE GENES. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 935-943.	0.9	4
207	Androgen Receptor Binding Studies on Heterozygotes in a Family with Androgen Insensitivity Syndrome. Biochemical and Molecular Medicine, 1995, 55, 31-37.	1.5	15
208	Modulation of glucose transport by parathyroid hormone and insulin in UMR 106–01, a clonal rat osteogenic sarcoma cell line. Journal of Molecular Endocrinology, 1995, 14, 263-275.	1.1	27
209	Defects of androgen receptor function: from sex reversal to motor neurone disease. Molecular and Cellular Endocrinology, 1995, 112, 133-141.	1.6	55
210	Disorders of sexual development. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 555-579.	1.0	4
211	Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar) Tj ETQq1 1 0.	.784314 rş	gBT/Overloc
212	Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Molecular Endocrinology, 1995, 9, 1396-1404.	3.7	29
213	Expression of parathyroid hormone-related peptide gene in the rat hypothalamus. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1993, 106, 647-650.	0.2	4
214	Calcitonin increases transcription of parathyroid hormone-related protein via cAMP. Molecular and Cellular Endocrinology, 1993, 94, 1-7.	1.6	42
215	Kennedy's disease: genetic diagnosis of an inherited form of motor neuron disease. Australian and New Zealand Journal of Medicine, 1993, 23, 187-192.	0.5	14
216	Related individuals with different androgen receptor gene deletions Journal of Clinical Investigation, 1993, 91, 1123-1128.	3.9	35

#	Article	IF	CITATIONS
217	Impaired suppression of gluconeogenesis induced by overexpression of a noninsulin-responsive phosphoenolpyruvate carboxykinase gene. Molecular Endocrinology, 1993, 7, 1456-1462.	3.7	23
218	Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes, 1993, 42, 1731-1736.	0.3	13
219	Regulation of gene transcription and proliferation by parathyroid hormone is blocked in mutant osteoblastic cells resistant to cyclic AMP. Molecular and Cellular Endocrinology, 1992, 87, 69-77.	1.6	8
220	Multiple endocrine neoplasia syndrome â€" type 2b. International Journal of Oral and Maxillofacial Surgery, 1992, 21, 110-114.	0.7	31
221	AN INTRAâ€THYROIDAL BRANCHIAL CYST: A CASE REPORT. ANZ Journal of Surgery, 1992, 62, 826-828.	0.3	20
222	Inhibition of Parathyroid Hormone Responsiveness in Clonal Osteoblastic Cells Expressing a Mutant Form of $3\hat{a}\in^2$ , $5\hat{a}\in^2$ -Cyclic Adenosine Monophosphate-Dependent Protein Kinase. Molecular Endocrinology, 1989, 3, 60-67.	3.7	30
223	Production of parathyroid hormone-related protein by a rat parathyroid cell line. Molecular and Cellular Endocrinology, 1989, 67, 107-112.	1.6	32
224	Sensitive Radiometric Assay for Chloramphenicol Acetyltransferase Using Automated HPLC. DNA and Cell Biology, 1988, 7, 509-513.	5.1	7
225	Parathyroid hormone-related protein purified from a human lung cancer cell line Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5048-5052.	3.3	720
226	A COMPARATIVE DOUBLEâ€BLIND TRIAL OF THE EFFECTIVENESS AND ANTIGENICITY OF SEMISYNTHETIC HUMAN INSULIN AND PURIFIED PORCINE INSULIN IN NEWLY TREATED DIABETIC SUBJECTS. Australian and New Zealand Journal of Medicine, 1986, 16, 206-210.	0.5	11
227	BASAL AND STIMULATED RELEASE OF CALCITONIN GENEâ€RELATED PEPTIDE (CGRP) IN PATIENTS WITH MEDULLARY THYROID CARCINOMA. Clinical Endocrinology, 1986, 25, 675-685.	1.2	45
228	Glucocorticoid Treatment Facilitates Cyclic Adenosine 3′,5′-Monophosphate-Dependent Protein Kinase Response in Parathyroid Hormone-Responsive Osteogenic Sarcoma Cells*. Endocrinology, 1986, 118, 2059-2064.	1.4	27
229	Identification of Calcitonin and Calcitonin Gene-Related Peptide Messenger Ribonucleic Acid in Medullary Thyroid Carcinomas by Hybridization Histochemistry*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1037-1043.	1.8	53
230	Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcified Tissue International, 1985, 37, 51-56.	1.5	193
231	Biosynthesis of Calcitonin by Human Lung Cancer Cells*. Endocrinology, 1985, 116, 749-755.	1.4	37
232	Selective activation of cyclic AMP dependent protein kinase by calcitonin in a calcitonin secreting lung cancer cell line. Biochemical and Biophysical Research Communications, 1984, 122, 1040-1046.	1.0	8
233	ADRENOMYELONEUROPATHY–CLINICAL and BIOCHEMICAL DIAGNOSIS. Australian and New Zealand Journal of Medicine, 1983, 13, 594-600.	0.5	21